Go Back

EANM Procedure Guidelines for Radioiodine Therapy of Differentiated Thyroid Cancer

The purpose of the present guidelines on the radioiodine therapy of differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians and other members of the DTC-treating community on how to ablate thyroid remnant or treat inoperable advanced DTC or both employing large 131I activities.

Radioiodine therapy is defined as the systemic administration of 131-sodium or potassium iodide (131I) for selective irradiation of thyroid remnants, microscopic DTC or other nonresectable or incompletely resectable DTC, or both purposes. Based on the primary goal of the therapy, there are two main forms of the procedure.